Inhibition of MALT1 by treatment with z-VRPR-fmk, or by expression of a catalytically inactive form of MALT1, decreased the expression of NF-κB target genes and dramatically reduced the viability and growth of cell lines derived from ABC DLBCL, but not from GCB DLBCL [74, 75]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.